ClinicalTrials.gg
RecruitingNCT05612022VAsoundUpdated Nov 29, 2024

Acoustic Analysis of VA Sounds

An observational study in End Stage Renal Disease and Hemodialysis Access Failure, sponsored by Mario Negri Institute for Pharmacological Research. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Mario Negri Institute for Pharmacological Research · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
44
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Kidney Failure, Chronic with a site in Italy — 14 open to participants now, 19 under way, 4 of them phase 3. Kidney Failure, Chronic · Italy.

Planned enrollment
14th of 16
44 · median 164
Started
2023
with 3 others
Observational
16 of 75
5 open now
Primary completion
2026-12
later than 5 of 18 live
Registered
63rd of 75
by date
Lead sponsor
3 of 75
Mario Negri Institute for Pharmacological Research

Among the 75 studies in Kidney Failure, Chronic with a site in Italy, this one is the 14th largest by planned enrollment of the 16 observational ones that give a count, is one of 4 that started in 2023, is one of 16 observational ones, reaches primary completion later than 5 of the 18 other live ones, and was the 63rd registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

14 of the 75 studies in Kidney Failure, Chronic with a site in Italy are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Kidney Failure, Chronic with a site in Italy, or all of them as a file.
02

Study summary

End-stage renal disease (ESRD) is a growing global health problem, strictly connected with progressive ageing population and longer survival of patients living on renal replacement therapy. The majority of ESRD patients is on hemodialysis (HD) treatment. A successful HD procedure requires a functioning vascular access (VA) to provide safe and long-lasting way to connect patient circulation to the artificial kidney. The current recommendation for VA is the native arteriovenous fistula (AVF), surgically created in the forearm by an anastomosis between a vein and an artery. The AVF, despite being the first-choice treatment, is still affected by high non-maturation and early failure rates, requiring in most of the cases, the creation of a new VA. An arteriovenous graft (AVG) is the second choice for a VA. Surgery is done using an artificial plastic tube that connects an artery to a vein. The AVG matures earlier than AVF (2/3 vs 6 weeks), but it is more prone to infections and has lower survival.

It would be important to identify patients at risk of VA failure, but there is currently a lack of adequate strategies for surveillance. A continuous monitoring of the VA function would help in identification of reduced blood flow and VA stenosis, that could be treated by interventional radiologists before AVF or AVG complete closure. Over the years, nurses and nephrologists got used to touch the VA and qualitatively evaluate its vibration, named "thrill", and the sounds emitted by the same using their stethoscope.

The purpose of this study is to assess the feasibility of VA sound recording and analysis and provide preliminary evidence of VA sound clinical validity and utility to assess, monitor and predict vascular remodelling occurring in AVFs and AVGs.

This is a single center prospective observational study involving the acquisition of VA sounds and Doppler US examinations in consenting patients with ESRD.

To reach this goal, two groups of ESRD patients in need of VA surgery to perform HD treatment will be involved:

Group 1. Patients with AVF as first line HD access option.

Group 2. Patients with AVG as first line HD access option.

03

Conditions studied

  • End Stage Renal Disease
  • Hemodialysis Access Failure

Keywords

  • AVF
  • AVG
  • VA sounds
  • acoustic analysis
  • VA remodelling
  • Doppler Ultrasound
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will be performed in patients with ESRD enrolled at the Nephrology and Dialysis Department of the ASST Papa Giovanni XXIII (Bergamo, Italy). VA sounds and Doppler US data will be collected.

The patients of both groups (AVF and AVG) will undergo visit V1 (screening and enrolment). On day 0 they will have the surgery for VA creation (V2). Then the study follow-up visits will be performed:

  • At 7, 14, 28, 42 and 60 days after VA surgery (V3, V4, V5, V6, V7)
  • Once every 3 months from the third month to two years after VA surgery (V8, ..., ENDV).

Patients will be asked to provide consent for the use of their clinical and laboratory data collected during routine clinical practice over 10 years following the end of this study. Refusal to this consent will not prevent from participating in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures.
  2. Patients in HD treatment that need a new VA or patients that entered the pre-dialysis program because of ESRD. In all these cases the treatment of first choice should be the creation of a distal autogenous AVF, the creation of an AVG or the proximalization of an occluded VA.

Exclusion criteria

Exclusion Criteria:

  1. for the creation of an autogenous AVF, for the AVG creation or the proximalization of a failed VA.
  2. Patients who use catheter to perform HD.
  3. Patients undergoing peritoneal dialysis.
  4. Patients with less than 2 years.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
44 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1. Patients with AVF as first line HD access option.

    24 consecutive patients in need of AVF enrolled at the Nephrology and Dialysis unit of the ASST-Papa Giovanni XXIII of Bergamo.

    Procedure: AVF creation

  • Group 2. Patients with AVG as first line HD access option.

    20 consecutive patients in need of AVG enrolled at the Nephrology and Dialysis unit of the ASST-Papa Giovanni XXIII of Bergamo.

    Procedure: AVG creation

Interventions

  • ProcedureAVF creation

    AVF is surgically created in the forearm by an anastomosis between a vein and an artery

  • ProcedureAVG creation

    Surgery is done using an artificial plastic tube that connects an artery to a vein

06

What researchers measure

Primary outcomes

  1. Low-high peak ratio (LHPR)

    Ratio between the amplitude of maximum peak in the range of lowfrequency (100-250 Hz) and the amplitude of the maximum peak at high frequency (500-750 Hz).

    Time frame: From v3 (day 7) to end visit (month 24): change from previous visit

Secondary outcomes

  1. Correlation coefficient between LHPR and Blood Flow Volume (BFV) during VA maturation.

    BFV is measured with Doppler ultrasonography (US).

    Time frame: From v3 (day 7) to VA maturation (v6, day 42): change from previous visit

  2. Correlation coefficient between LHPR and Blood Flow Volume (BFV) after VA maturation.

    BFV is measured with Doppler ultrasonography (US).

    Time frame: From v7 (day 60) to end visit (month 24): change from previous visit

07

Study locations

1 of 1 sites recruiting
  • ASST HPG23 Unità di Nefrologia e Dialisi
    Bergamo, BG 24127, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.

Of 132 non-industry observational studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's planned 43 months is above that.

Counting every sponsor, half of 151 studies reached it within 29 months; a quarter within 11 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Nov 10, 2022
StartActual
May 9, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05612022
Responsible party
Sponsor
First posted
Nov 10, 2022
Start date
May 9, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 29, 2024

Study contacts

Anna Caroli
Contact
anna.caroli@marionegri.it
003903545351
Sofia Poloni
Contact
sofia.poloni@marionegri.it
003903545351

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion